लोड हो रहा है...

Real‐World Data on Prognostic Factors for Overall Survival in EGFR Mutation‐Positive Advanced Non‐Small Cell Lung Cancer Patients Treated with First‐Line Gefitinib

BACKGROUND. This study aimed to identify independent prognostic factors for overall survival (OS) of patients with advanced non‐small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation and receiving gefitinib as first‐line treatment in real‐world practi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Yao, Zong‐Han, Liao, Wei‐Yu, Ho, Chao‐Chi, Chen, Kuan‐Yu, Shih, Jin‐Yuan, Chen, Jin‐Shing, Lin, Zhong‐Zhe, Lin, Chia‐Chi, Chih‐Hsin Yang, James, Yu, Chong‐Jen
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AlphaMed Press 2017
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5599189/
https://ncbi.nlm.nih.gov/pubmed/28507206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0331
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!